Abstract
Clinical outcome in patients with primary nodal diffuse large B-cell lymphomas (DLBCL) is correlated with expression of inhibitors of the intrinsic apoptosis pathway, including XIAP.
XIAP suppresses apoptosis through inhibiting active caspases-3, -7 and -9. In this study we XIAP antagonist-sensitive cases were characterized by high expression levels of XIAP, relatively low expression levels of Bcl-2, and by constitutive caspase-9 activation.
These data indicate that the small-molecule XIAP antagonist can induce apoptosis in cultured DLBCL cells and therefore should be considered for possible development as a therapy for these patients. In vitro sensitivity to the XIAP antagonist can be predicted based on biological markers suggesting the possibility of pre-defining patients most likely to benefit from XIAP antagonist therapy.
Introduction
Diffuse large B-cell lymphomas (DLBCLs) account for 30-40% of adult Non-Hodgkin lymphoma. 1 At present, the standard therapy for DLBCL is a combination of intensive chemotherapy (CHOP) with rituximab. 2 Although this approach results in a considerable number of cured DLBCL patients, the disease remains eventually fatal in 30-40% of the cases. 3 Fatal outcome is usually due to chemotherapy resistance manifesting in failure to achieve complete remission or the occurrence of an early relapse. Many in vitro studies have demonstrated that inhibition of the apoptosis signaling pathways is an important factor causing chemotherapy resistance. 4, 5, 6, 7 Recently, using microarray expression profiling of primary nodal DLBCL, we have demonstrated that a subgroup of chemotherapy refractory DLBCL is characterized by high expression levels of both pro-and anti-apoptotic genes. 8 Subsequently, we revealed that high expression levels of pro-apoptotic genes are associated with constitutive activation of the intrinsic, caspase-9-mediated apoptosis pathway and that apoptosis is inhibited downstream of caspase-9 activation. 9 Direct inhibitors of the downstream effector caspases of the intrinsic and extrinsic apoptosis pathways are the Inhibitor of Apoptosis Proteins (IAPs). At present, eight members of the IAP family have been identified in humans, including XIAP (X-linked inhibitor of apoptosis).
XIAP appears to be one of the most potent inhibitors of the apoptosis cascade and suppresses apoptosis induced by many agents, including TNF, TRAIL, Fas-L, staurosporine, etoposide and paclitaxel. 10, 11 The XIAP protein inhibits caspases -3, -7, and -9, but not caspases-1, -6, -8, or -10. 12,13 XIAP contains three so-called baculoviral IAP repeat (BIR)
domains. 14 The second BIR domain of XIAP (BIR2) binds and inhibits caspases-3 and -7, while the third BIR domain (BIR3) inhibits caspase-9. 15, 16 XIAP is expressed in some normal tissues and is overexpressed in many malignancies. 17, 18, 19 In DLBCL, XIAP expression is correlated with a poor clinical outcome. 20 Therefore, neutralizing the effect of XIAP, resulting in selective induction of apoptosis of the tumor cells might be a promising new therapeutic approach for chemotherapy refractory DLBCL.
Small-molecule antagonists that specifically interfere with the inhibitory function of XIAP have been described, including the phenylurea-based compound N-[(5R)-6- in a humidified atmosphere. Non-neoplastic T-cells were removed by using super paramagnetic dynabeads coated with anti-CD3 antibodies (Dynal, Wirral, England). The resulting tumor cell fractions contained in all cases < 5% contaminating non-neoplastic cells.
Germinal center B-cells were FACS-sorted from tonsil B-cell suspensions using antibodies against the cell surface markers CD38 (clone HB7, BD biosciences, San Jose, CA, USA) and IgD (DakoCytomation, Glostrup, Denmark).
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The DLBCL cell lines used for this study included: HT, SUDHL4 and SUDHL5 (originally obtained from DSMZ, Braunschweig, Germany). As a positive control for detection of apoptosis, Nalm6 cells were used. 9 Cell lines were cultured in RPMI 1640 medium (BioWhittaker, Cambrex, Belgium) containing 10% fetal calf serum and 100 IU penicillin/100 µg/ml streptomycin. Etoposide (VP16, Sigma, St.Louis, MO, USA) was used to asses sensitivity to chemotherapy-induced apoptosis because it activates the intrinsic pathway 9, 30 and is as such representative of the many chemotherapeutic drugs used in the treatment of DLBCL. 32, 33, 34, 35 Moreover, it lacks auto-fluorescence making etoposide very suitable for FACS analysis.
DLBCL cell lines were incubated with 500nM etoposide for 4, 7, 16 and 24 hours at 37°C.
Sensitivity to rituximab induced cell death was determined by incubating DLBCL cells with 10µg/ml rituximab (Roche, Basel, Switzerland) for 15 minutes at room temperature.
Subsequently, normal human serum was added as source of complement and cells were incubated at 37°C for 24 hours. Dose response curves showed that for etoposide-and rituximab-induced cell death, 500nM etoposide and 10µg/ml rituximab were the optimal cell death inducing concentrations in DLBCL cell lines, respectively (data not shown).
The effect of XIAP antagonists on etoposide-induced cell death was tested with increasing concentrations of XIAP antagonist 1396-12 in combination with 500 nM for 16 hours.
Cell death of primary cells and DLBCL cell lines was determined as described previously. 30 Briefly, cell death was detected using a standard number of fluorescent beads (Fluorospheres, Becton Dickinson, USA) in combination with 7AAD (7-amino-actinomycin, ViaProbe, BD Pharmingen, Belgium) to determine the number of viable (7AAD negative) cells per 2500 beads for each individual experiment. Fluorescence was detected using a FACS Calibur flow cytometer and analyzed using CELL-Quest software (both Becton Dickinson, San Jose, CA, USA). All tests were performed in triplicate.
Detection of caspase-3/7 activity
Caspase-3/7 activity was determined using a fluorogenic substrate according to the manufacturer's instructions (Roche, Mannheimm, Germany). Cells were lysed and incubated with the DEVD-rhodamine 110 substrate for one hour at 37°C. Subsequently, the amount of free rhodamine was determined with a 492 nm excitation filter and a 535 nm emission filter using a microplate fluorescence reader (TECAN spectrafluor, Männedorf, Switzerland).
only.
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RT-MLPA analysis
RNA of primary cells and DLBCL cell lines were prepared using RNbee solution (Tel-test Inc., Friendswood, TX, USA) according to the manufacture's recommendations. RT-Multiplex Ligation-dependent Probe Amplification (RT-MLPA) was performed on total RNA as described previously.
36,9 Data were analyzed with Genotype and GeneScan software (Applied Biosystems, Warrington, UK). As internal reference the house keeping gene ß-glucuronidase (GUS-B) was used to minimize possible effects of unequal amounts of mRNA.
siRNA analysis
In SUDHL4 cells, Bcl-2 expression was down regulated using si-RNA analysis. Transfection of SUDHL4 cells was performed using Transpei (Eurogentec, San Diego, CA, USA).
Transfection efficiency of SUDHL4 was 70-80%. Transfection-associated cell death was negligible. Before transfection of si-RNA, cells were washed with RPMI 1640 medium containing 10% fetal calf serum. Cells were transfected with 100 nM control non-targeting siRNA pool or Bcl-2 specific si-RNA (both provided by Dharmacon). Transfection efficiency was determined by FACS analysis of fluorescent siRNA siGLO Lamin A/C.
Western blot analysis
Total protein extracts were prepared from SUDHL4, at 24, 48, 72 and 96 hours after transfection and after incubation with 10µM of the XIAP antagonist for western blot analysis, as described previously. 37 Cells were washed with PBS and resuspended in lysis buffer (50 mM Tris/HCl, pH 8.0, 0.5% NP-40, 5 mM EDTA) containing protease inhibitors. Cytosolic fractions were generated using a digitonin-based subcellular fractionation technique, as described previously. 38 In brief, cells were collected, washed in ice-cold PBS pH 7.2 and resuspended in cytosolic extraction buffer (250mM sucrose, 70mM KCl, 137mM NaCl, 4.3mM Na 2 HPO 4 ), supplemented with protease inhibitor cocktail, 250µM PMSF, and 200µg/ml digitonin. After incubation for 5 minutes at 4°C, the cytosolic fraction was obtained. only.
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Statistical analysis
Analyses were performed using SPSS software (version 11.5, SPSS Inc, Chicago, IL, USA).
The Mann Whitney-U test was used to compare means between groups. P-values below 0.05 were considered significant. We further investigated if the XIAP antagonist also induces apoptosis in clinically chemotherapy refractory DLBCL. Clinical data were available for seventeen of the twenty DLBCL patients. The XIAP antagonist was similarly effective in samples obtained from both chemotherapy refractory and responsive DLBCL patients. ABC-like DLBCL tended to be more frequently sensitive to the XIAP antagonist than GCB like DLBCL, although this was not statistically significant (Table 1) .
Previously, we demonstrated that expression profiling of apoptosis-related genes using RT-MLPA analysis separates DLBCL in 2 groups: one group with relatively low levels of both pro-and anti-apoptotic genes and one group with high expression levels of these apoptosis regulating genes. 9 The XIAP antagonist appeared to be especially effective in DLBCL cases with high expression levels of pro-and anti-apoptotic genes (Table 1, p=0.02).
XIAP antagonist-induced cell death is dependent on caspase-9 activation
The effect of the XIAP antagonist on apoptosis sensitivity was further investigated in three DLBCL derived cell lines: SUDHL4, SUDHL5 and HT. All three cell lines resistant to etoposide were sensitive to the XIAP antagonist (Figure 2A-B) . In simultaneous experiments, addition of the pan-caspase inhibitor z-VAD-fmk completely blocked killing induced by the XIAP antagonist, indicating that the induced cell death is caspase-dependent. Moreover, only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From induction with the XIAP antagonist resulted in clearly detectable caspase-3/7 activity with a maximal increase after 7-16 hours of incubation. Experiments with a specific caspase-9 inhibitor, LEHD-FMK showed that the observed cell death is caspase-9-dependent ( Figure   2C-D) . Previously, we demonstrated that SUDHL4, SUDHL5 and HT showed constitutive caspase 9 activation and that incubation with the XIAP antagonist did not result in an increase in caspase 9 activation. 9 As expected, also no additional increase in mitochondrial cytochrome c release in the cytoplasm or Bax expression was observed after incubation with the XIAP antagonist ( Figure 2E ).
Sensitivity to the XIAP antagonist correlates with high expression levels of XIAP and with low levels of Bcl-2 expression
We investigated whether sensitivity to the XIAP antagonist in DLBCL samples correlates with expression levels of XIAP and with expression of other apoptosis inhibitors; Bcl-2, Bcl-X L , MCL1 and cIAP2. Expression levels were detected at the mRNA level using RT-MLPA analysis. The strongest apoptosis-inducing effect of the XIAP antagonist was observed in DLBCL samples with relatively high levels of XIAP (p=0.004, Figure 3 ). When investigated in non-neoplastic cells, PBMCs were found to express high levels of XIAP, whereas XIAP expression levels were very low in GC B-cells ( Figure 3 ). Thus sensitivity to the 1396-12 is not determined solely by XIAP protein levels.
When comparing XIAP antagonist-sensitive DLBCL (LD 50 <39µM) with resistant cases (LD 50 values ≥ 39µM), we found that sensitive cases were characterized by relatively high expression levels of MCL1 and cIAP2 (p=0.01 and p=0.005, respectively) and low expression levels of Bcl-2 (p=0.04, Figure 4A ). Expression levels of Bcl-X L did not significantly correlate with the response to the XIAP antagonist.
To further substantiate if Bcl-2 expression is involved in resistance to the XIAP antagonist in Figure 5C ).
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Discussion
Previous studies have shown that inhibition of the intrinsic apoptosis pathway is an important cause of chemotherapy resistance in DLBCL. 4, 5, 6, 7, 8 We have recently demonstrated that the majority of chemotherapy refractory DLBCL are characterized by constitutive caspase-9 activation with concomitant high expression levels of downstream apoptosis inhibitors, including XIAP. 8, 9 In these cases resistance to chemotherapy-induced apoptosis was not due to failure to activate the intrinsic apoptosis pathway by chemotherapy, but was caused by inhibition of the downstream convergence apoptosis pathway. An important candidate that causes this downstream inhibition is XIAP, which interacts with active caspase-9 and active effector caspases-3 and -7. The notion that the XIAP antagonist only de-represses caspase-3/7 inhibition also explains that the XIAP antagonist does not induce apoptosis in non-neoplastic germinal center B-cells and PBMC B-cells from healthy donors. 24 In these cells, the intrinsic apoptosis pathway is not constitutively activated 9 and thus relieving the apoptosis blockade will not result in apoptosis.
Furthermore, these findings explain why the XIAP antagonist did not sensitize DLBCL cells to etoposide-induced apoptosis, because the intrinsic pathway is already activated in XIAP sensitive DLBCL cells, which cannot be further activated by etoposide. 9 In this study we also show that the XIAP antagonist 1396-12 is active as a single agent and can directly induce apoptosis. Compared with conventional agents used in the treatment of DLBCL, the XIAP antagonist can induce apoptosis, even in cases with relatively low levels of etoposide-or rituximab-induced cell death. In addition, almost no XIAP antagonist-induced cell death was observed in normal healthy cells, whereas rituximab was more toxic to normal healthy cells. Rodent toxicology studies also suggest that the XIAP antagonist is well tolerated, causing essentially no detectable hematopoietic toxicity or injury to vital organs at doses that achieve significant anti-tumor activity. 21 To understand the variation in response to the XIAP antagonists between the DLBCL samples, we correlated the response to the XIAP antagonist with expression of XIAP and other apoptosis-inhibiting genes implicated in the intrinsic apoptosis pathway. Similar to previous observations for leukemia cells 24 , the apoptosis-inducing effect of the XIAP antagonist was stronger in samples with relatively high levels of XIAP expression. However, Survivin, c-Flip and Pi-9) as described previously.
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